Search Results

You are looking at 1 - 10 of 52 items for :

Clear All
Full access

John Glaspy

trials of ESAs among patients with cancer Distinguish the benefits of ESAs among patients with cancer Evaluate when to use ESAs among patients with cancer Anemia is frequently encountered in patients with cancer and is often multifactorial, with

Full access

Young D. Chang, Jae-Woo Jung, Ritika Oberoi-Jassal, Jongphil Kim, Sahana Rajasekhara, Meghan Haas, Joshua Smith, Vijay Desai, Kristine A. Donovan and Diane Portman

Assessment Scale (ESAS) has well-established reliability and validity when used in patients with cancer as a routine self-assessment tool. 22 Patients use the ESAS to score their average symptom severity during the 24 hours before presenting for an

Full access

Jennifer M. Hinkel, Edward C. Li and Stephen L. Sherman

(ESAs), blood transfusions, and iron supplementation to maintain hemoglobin levels in patients with cancer. Each of these interventions has complexities and, in some cases, controversies. Moreover, anemia and the interventions used to counter it can have

Full access

George M. Rodgers

Cancer- and Chemotherapy-Induced Anemia during its early years and have chaired it since 2004. Major changes in the NCCN Guidelines on anemia over the years have focused on 2 topics: erythropoiesis-stimulating agent (ESA) safety and the increasing use of

Full access

Anat Gafter-Gvili, David P. Steensma and Michael Auerbach

More than a decade has passed since Auerbach et al 1 presented the first study demonstrating synergy of intravenous (IV) iron with erythropoiesis-stimulating agents (ESAs) for correcting anemia in patients receiving chemotherapy for malignant

Full access

Jeffrey Crawford and George M. Rodgers

Iron for Cancer-Related Anemia Dr. Rodgers discussed the use of IV iron to optimize erythropoietic growth factor therapy or to minimize the need for it. Cancer-related anemia can be treated with erythropoiesis-stimulating agents (ESAs), red blood cell

Full access

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic and Alva B. Weir III

-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, these

Full access

Linda Watson, Siwei Qi, Andrea DeIure, Eclair Photitai, Lindsi Chmielewski and Louise Smith

Assessment System (ESAS-r) 8 , 9 and the Canadian Problem Checklist (CPC), 10 selected in alignment with the national reporting criteria established by the Canadian Partnership Against Cancer (CPAC). 11 In the process of integrating these patient

Full access

Michael Auerbach and Harold Ballard

Edited by Kerrin G. Robinson

of erythropoietic agents in oncology . Expert Opin Emerg Drugs 2005 ; 10 : 553 – 567 . 6. Collins A . Trend in iron testing and IV iron dosing in cancer patients receiving chemotherapy and ESA versus dialysis patients . Presented at

Full access

Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt and Pamela S. Becker

granulocyte-colony stimulating factors (G-CSFs), granulocyte-macrophage colony-stimulating factors, erythropoiesis-stimulating agents (ESAs), and other measures to manage cancer and chemotherapy-associated cytopenias. 11 , 12 These guidelines are based on the